Skip to main content

FDA Says Shortage of GLP-1 Tirzepatide (Mounjaro, Zepbound) Is Over

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 19, 2024.

By Ernie Mundell HealthDay Reporter

THURSDAY, Dec. 19, 2024 -- The U.S. Food and Drug Administration re-issued a decision first made by the agency in October that a shortage of the diabetes/weight-loss medication tirzepatide is over.

Tirzepatide includes blockbuster injected GLP-1 medications Mounjaro (for diabetes) and Zepbound (for weight loss).

The FDA first announced two months ago that any shortage of the medications observed during the summer was over.

However, it was forced to "re-evaluate" that decision after demands by the Outsourcing Facilities Association (OFA), a trade group for compounding pharmacists, which sued the agency claiming that tirzepatide was still in short supply.

As long as the drug shortage was declared, compounding pharmacies were still eligible to produce their own versions of Zepbound/Mounjaro.

However, Thursday's FDA announcement effectively puts an end to that, and compounding pharmacies must now cease producing the lucrative drugs within a set time period.

For many compounding pharmacies that date is 60 days from today (Feb.18) and for "bulk" compounding pharmacies the date is 90 days away (March 19), the FDA said in a statement.

"FDA may still take action regarding violations of any other statutory or regulatory requirements, such as to address findings that a product may be of substandard quality or otherwise unsafe," the agency noted.

Eli Lilly, the maker of Zepbound and Mounjaro, had pushed back against the OFA's assertion that shortages of tirzepatide were still in place, and has also claimed that versions of the drug made by compounded pharmacies are often "untested, unapproved knockoffs," according to NBC News.

As for other popular GLP-1s, the FDA listed these ongoing shortages:

Sources

  • FDA announcement, Dec. 19, 2024
  • NBC News

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted December 2024

Read this next

FDA and Novo Nordisk Alert Consumers to Counterfeit Ozempic

MONDAY, April 21, 2025 -- The U.S. Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging consumers to be on the lookout for counterfeit Ozempic...

First Weight-Loss Pill From Lilly, Orforglipron, Shows Promising Results

FRIDAY, April 18, 2025 — A new pill designed to help with weight loss and blood sugar control is showing promise in early studies. Eli Lilly said its experimental drug...

Pregnancy Complications Affect Future Heart Health

FRIDAY, April 18, 2025 -- Complications during pregnancy can mean a woman’s future heart health is at risk, particularly if she is overweight or obese, a new study...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.